231 completed, 67 terminated, 19 withdrawn, 17 recruiting. 151 Phase 1, 128 Phase 2, 44 Not applicable, 27 Phase 3, 3 Early Phase 1.
Follow Sezary Syndrome: new trials by email Literature Review of Sezary Syndrome trials Research Report on Sezary Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) blood sampling - Sezary Syndrome, Ichthyosis, Lamellar | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2026-04-01 | 2026-03-17 | |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 37 | 2026-03-30 | 2026-04-17 |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance Poteligeo 20mg - Mycosis Fungoides, Sezary Syndrome | Recruiting | Kyowa Kirin Co., Ltd. | 15 | 2025-05-02 | 2026-11-03 | |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Recruiting | Fondazione Italiana Linfomi - ETS | 400 | 2025-02-27 | 2025-12-02 | |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab Non-Interventional Study - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Recruiting | City of Hope Medical Center | 100 | 2024-12-06 | 2026-11-04 | |
| Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study Follow-up - Mycosis Fungoides/Sezary Syndrome, Cutaneous T Cell Lymphoma | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 460 | 2024-11-01 | 2024-10-21 | |
| Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Completed | Fondazione Italiana Linfomi - ETS | 100 | 2024-06-06 | 2026-06-01 | |
| A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma molecular subtype based treatment - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma | Recruiting | Peking University First Hospital | 100 | 2024-05-09 | 2024-05-31 | |
| Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome Tulmimetostat - Mycosis Fungoides, Sezary Syndrome | Phase 1 | Active not recruiting | Washington University School of Medicine | 24 | 2024-01-09 | 2026-09-16 |
| Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS). - Cutaneous T-Cell Lymphoma | Recruiting | Instituto de Investigación Biomédica de Salamanca | 100 | 2024-01-01 | 2025-05-01 | |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
Showing 20 of 367. Sign in to see all of them.
Mycosis Fungoides (355) · Lymphoma, T-Cell, Cutaneous (331) · Leukemia, Lymphocytic, Chronic, B-Cell (239) · Lymphoma, Follicular (238) · Lymphoma, Large B-Cell, Diffuse (237) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (234) · Lymphoma, B-Cell, Marginal Zone (233) · Lymphoma, Mantle-Cell (233) · Lymphoma, Non-Hodgkin (228) · Burkitt Lymphoma (226) · Hodgkin Disease (218) · Lymphoma, Large-Cell, Immunoblastic (216) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (183) · Lymphoma, Large-Cell, Anaplastic (181)
Hemic and Lymphatic Diseases (367) · Neoplasms by Histologic Type (367) · Immunoproliferative Disorders (366) · Lymphatic Diseases (366) · Immune System Diseases (365) · Lymphoma, T-Cell (351) · Lymphoproliferative Disorders (337) · Neoplasms (329) · Hematologic Diseases (258) · Leukemia, Lymphoid (257) · Pathological Conditions, Signs and Symptoms (253) · Pathologic Processes (251) · Disease Attributes (249) · Lymphoma, B-Cell (245) · Chronic Disease (239)
Peripheral Blood Stem Cell Transplantation (39) · fludarabine phosphate (36) · Cyclophosphamide (31) · Mycophenolic Acid (28) · Cyclosporine (25) · Whole-Body Irradiation (24) · Tacrolimus (22) · Antilymphocyte Serum (18) · Busulfan (18) · Methotrexate (16) · Radiotherapy (16) · Filgrastim (14) · Flow Cytometry (14) · Etoposide (13) · Lenalidomide (11)
National Cancer Institute (NCI) (48) · Fred Hutchinson Cancer Center (32) · City of Hope Medical Center (17) · Northwestern University (17) · Mayo Clinic (13) · Case Comprehensive Cancer Center (12) · Memorial Sloan Kettering Cancer Center (12) · European Organisation for Research and Treatment of Cancer - EORTC (11) · National Institutes of Health Clinical Center (CC) (10) · Jonsson Comprehensive Cancer Center (8) · Roswell Park Cancer Institute (7) · Vanderbilt-Ingram Cancer Center (7) · Wake Forest University Health Sciences (7) · M.D. Anderson Cancer Center (6) · UNC Lineberger Comprehensive Cancer Center (6)
United States (308) · Italy (25) · Germany (21) · France (17) · Switzerland (16) · United Kingdom (15) · Spain (14) · Canada (11) · Belgium (10) · Austria (8) · Australia (7) · Netherlands (6) · Israel (4) · Poland (4) · South Korea (4)
Timothy M. Kuzel, MD (5) · Brenda Sandmaier (4) · David Maloney (4) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Ajay Gopal (3) · Barbara Pro, MD (3) · David G. Savage, MD (3) · Kyoo H. Lee, MD (3) · Larisa J. Geskin, M.D. (3) · Paul Martin (3) · Thomas E. Witzig, MD (3) · Abhinav Deol, M.D. (2) · Alex Shalaurov, MD, PhD (2) · Alison Moskowitz, MD (2)
PMID 32632956, PMID 32499241, PMID 23770157, PMID 33883258, PMID 10552943, PMID 10764422, PMID 11231324, PMID 11410496, PMID 11675364, PMID 11895901, PMID 12525530, PMID 12543862, PMID 14630685, PMID 15107815, PMID 15459300, PMID 16135477, PMID 16148284, PMID 16710026, PMID 17020988, PMID 17119113, PMID 17397698, PMID 17515522, PMID 17854367, PMID 18327587, PMID 18463792, PMID 18698002, PMID 19170225, PMID 19199905, PMID 19451403, PMID 19789320, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 21135857, PMID 21247755, PMID 21355097, PMID 21498721, PMID 21715313, PMID 21719601, PMID 22259028, PMID 22480131, PMID 22924950, PMID 22981498, PMID 23045580, PMID 23256542, PMID 23358983, PMID 23393050
P30CA015704 (15), P30CA033572 (12), P30CA015083 (9), P30CA043703 (8), P30CA072720 (7), P30CA068485 (6), P01CA018029 (5), P30CA016086 (4), P30CA016672 (4), P30CA022453 (4), P30CA060553 (4), U01CA062491 (4), U01CA062502 (4), U01CA076576 (4), U01CA099168 (4)